Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Comparación de la quimioterapia con BEACOPP escalonado y la quimioterapia con ABVD para pacientes con linfoma de Hodgkin avanzado o temprano no favorable

Esta versión no es la más reciente

ver la versión actual 25 mayo 2017

Información

DOI:
https://doi.org/10.1002/14651858.CD007941.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 10 agosto 2011see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Hematología

Copyright:
  1. Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Kathrin Bauer

    Correspondencia a: Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

    [email protected]

  • Nicole Skoetz

    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

  • Ina Monsef

    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

  • Andreas Engert

    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

  • Corinne Brillant

    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

Contributions of authors

Kathrin Bauer: drafting of the protocol, data extraction, writing of the review.

Nicole Skoetz: methodological expertise.

Ina Monsef: development of the search strategy.

Andreas Engert: clinical expertise.

Corinne Brillant: conception of the review, writing of the protocol, data extraction, statistical expertise, grant application.

All authors have read and accepted the final version of the review.

Sources of support

Internal sources

  • No sources of support supplied

External sources

  • This review was funded by the Federal Ministry of Education and Research, Germany.

Declarations of interest

KB, NS, IM and CB: none known.

AE is chairman of the German Hodgkin Study Group.

Acknowledgements

We are grateful to the following persons for their comments and improving the protocol and review:

Professor Lena Specht and Professor Keith Wheatley, Editors of the Cochrane Haematological Malignancies Group, Céline Fournier, consumer feedback, Sabine Kluge and Bettina Schmidtke of the Cochrane Haematological Malignancies Group.

Furthermore, we would like to thank Jeremy Franklin for providing the recalculate data of the HD9 trial.

Version history

Published

Title

Stage

Authors

Version

2017 May 25

Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma

Review

Nicole Skoetz, Andrea Will, Ina Monsef, Corinne Brillant, Andreas Engert, Bastian von Tresckow

https://doi.org/10.1002/14651858.CD007941.pub3

2011 Aug 10

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma

Review

Kathrin Bauer, Nicole Skoetz, Ina Monsef, Andreas Engert, Corinne Brillant

https://doi.org/10.1002/14651858.CD007941.pub2

2009 Jul 08

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma

Protocol

Corinne Brillant, Kathrin Bauer, Christine Herbst, Ina Monsef, Nicole Skoetz, Andreas Engert

https://doi.org/10.1002/14651858.CD007941

Differences between protocol and review

We restricted subgroup and sensitivity analysis to the primary outcomes, which was not clearly described within the protocol.

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.